Opus Genetics, Inc. 8-K

What Happened
Opus Genetics, Inc. (IRD) filed an 8-K on April 22, 2026 reporting results from its April 20, 2026 annual meeting. Stockholders elected nine directors to one-year terms, ratified Ernst & Young LLP as the independent registered public accounting firm for 2026, approved the advisory "say-on-pay" vote for named executive officer compensation, and approved an amendment to increase authorized common shares from 125 million to 250 million.

Key Details

• Board elections: Nine directors elected; votes for nominees ranged ~33.9M–35.1M with broker non-votes of 12,043,097. Notably, James S. Manuso received 33,885,159 votes for and 1,348,112 withheld.
• Auditor ratification: Ernst & Young LLP ratified — 46,844,680 for, 315,324 against, 116,364 abstentions.
• Say-on-pay (advisory): Approved — 34,862,743 for, 259,749 against, 110,779 abstentions; broker non-votes 12,043,097.
• Authorized shares amendment: Approved — 45,360,642 for, 1,486,247 against, 429,479 abstentions; increase from 125,000,000 to 250,000,000 common shares.

Why It Matters
These votes confirm the company’s governance leadership for the coming year and shareholder support for management’s pay practices (advisory). Ratification of Ernst & Young maintains continuity in external audit oversight. The approved increase in authorized common shares materially expands the company’s capacity to issue equity (for financing, employee plans, or other corporate purposes), which investors should note when monitoring potential dilution or future capital-raising activity.